Kinase rearrangements and therapeutic targets in Ph-like ALL
| Kinase . | Potential TKI . | Number of gene partners . | Number of cases . | 5′ genes . |
|---|---|---|---|---|
| ABL1 | Dasatinib | 6 | 14 | ETV6, NUP214, RCSD1, RANBP2, SNX2, and ZMIZ1 |
| ABL2 | Dasatinib | 3 | 7 | PAG1, RCSD1, and ZC3HAV1 |
| CSF1R | Dasatinib | 1 | 4 | SSBP2 |
| PDGFRB | Dasatinib | 4 | 11 | EBF1, SSBP2, TNIP1, and ZEB2 |
| CRLF2 | JAK2 inhibitor | 2 | 30 | IGH and P2RY8 |
| JAK2 | JAK2 inhibitor | 10 | 19 | ATF7IP, BCR, EBF1, ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, and TPR |
| EPOR | JAK2 inhibitor | 2 | 9 | IGH and IGK |
| DGKH | Unknown | 1 | 1 | ZFAND3 |
| IL2RB | JAK1/JAK3 inhibitor | 1 | 1 | MYH9 |
| NTRK3 | Crizotinib | 1 | 1 | ETV6 |
| PTK2B | FAK inhibitor | 2 | 1 | KDM6A and STAG2 |
| TSLP | JAK2 inhibitor | 1 | 1 | IQGAP2 |
| TYK2 | TYK2 inhibitor | 1 | 1 | MYB |
| Kinase . | Potential TKI . | Number of gene partners . | Number of cases . | 5′ genes . |
|---|---|---|---|---|
| ABL1 | Dasatinib | 6 | 14 | ETV6, NUP214, RCSD1, RANBP2, SNX2, and ZMIZ1 |
| ABL2 | Dasatinib | 3 | 7 | PAG1, RCSD1, and ZC3HAV1 |
| CSF1R | Dasatinib | 1 | 4 | SSBP2 |
| PDGFRB | Dasatinib | 4 | 11 | EBF1, SSBP2, TNIP1, and ZEB2 |
| CRLF2 | JAK2 inhibitor | 2 | 30 | IGH and P2RY8 |
| JAK2 | JAK2 inhibitor | 10 | 19 | ATF7IP, BCR, EBF1, ETV6, PAX5, PPFIBP1, SSBP2, STRN3, TERF2, and TPR |
| EPOR | JAK2 inhibitor | 2 | 9 | IGH and IGK |
| DGKH | Unknown | 1 | 1 | ZFAND3 |
| IL2RB | JAK1/JAK3 inhibitor | 1 | 1 | MYH9 |
| NTRK3 | Crizotinib | 1 | 1 | ETV6 |
| PTK2B | FAK inhibitor | 2 | 1 | KDM6A and STAG2 |
| TSLP | JAK2 inhibitor | 1 | 1 | IQGAP2 |
| TYK2 | TYK2 inhibitor | 1 | 1 | MYB |
Data are from Roberts et al.22